Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.41 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21490096 | 0.93 | SMYD3 (0.55) | SMYD3 | |
| SCHEMBL19710530 | 0.93 | SMYD3 (0.55) | SMYD3 | |
| SCHEMBL8950348 | 0.80 | HTR4 (0.41) | SMYD3SMN1; SMN2L3MBTL1KDM4EHTT | |
| SCHEMBL12495652 | 0.77 | BAZ2B (0.42) | SMN1; SMN2KDM4EHTTALDH1A1LMNA | |
| SCHEMBL2214845 | 0.70 | — | — | |
| SCHEMBL19710187 | 0.69 | SMYD3 (0.50) | SMYD3 | |
| SCHEMBL21490181 | 0.69 | SMYD3 (0.50) | SMYD3 | |
| SCHEMBL12851851 | 0.69 | CNR1 (0.42) | HPGDSMYD3KDM4EHTTPDE4B | |
| SCHEMBL10364892 | 0.69 | HSD11B1 (0.52) | HPGDSMN1; SMN2KDM4EHTTALDH1A1 | |
| SCHEMBL12496155 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188085-B2 | Antifungal agents | MERCK SHARP & DOHME CORP. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20100113439-A1 | Antifungal agents | MERCK & CO., INC. (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113439-A1 | Antifungal agents | GMDS, GBA3, UGGT1 | HPGD 413/4885SMYD3 3041/4885SMN1; SMN2 3768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.